FI4069690T3 - Triatsolisienilääkeyhdiste pc945:n polymorfeja - Google Patents

Triatsolisienilääkeyhdiste pc945:n polymorfeja Download PDF

Info

Publication number
FI4069690T3
FI4069690T3 FIEP20824979.7T FI20824979T FI4069690T3 FI 4069690 T3 FI4069690 T3 FI 4069690T3 FI 20824979 T FI20824979 T FI 20824979T FI 4069690 T3 FI4069690 T3 FI 4069690T3
Authority
FI
Finland
Prior art keywords
crystalline form
compound
pharmaceutical composition
spp
composition according
Prior art date
Application number
FIEP20824979.7T
Other languages
English (en)
Finnish (fi)
Inventor
Christopher John Wallis
Gerald Steele
Suzanne Buttar
Osama Suleiman
Julian Northen
John Mykytiuk
Jamie Marshall
Original Assignee
Pulmocide Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmocide Ltd filed Critical Pulmocide Ltd
Application granted granted Critical
Publication of FI4069690T3 publication Critical patent/FI4069690T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP20824979.7T 2019-12-06 2020-12-04 Triatsolisienilääkeyhdiste pc945:n polymorfeja FI4069690T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1917867.2A GB201917867D0 (en) 2019-12-06 2019-12-06 Polymorphs
PCT/GB2020/053107 WO2021111142A1 (en) 2019-12-06 2020-12-04 Polymorphs of triazole antifungal compound pc945

Publications (1)

Publication Number Publication Date
FI4069690T3 true FI4069690T3 (fi) 2025-01-21

Family

ID=69171938

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20824979.7T FI4069690T3 (fi) 2019-12-06 2020-12-04 Triatsolisienilääkeyhdiste pc945:n polymorfeja

Country Status (26)

Country Link
US (2) US12491182B2 (cg-RX-API-DMAC7.html)
EP (2) EP4069690B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023505227A (cg-RX-API-DMAC7.html)
KR (1) KR20220110726A (cg-RX-API-DMAC7.html)
CN (1) CN114746415B (cg-RX-API-DMAC7.html)
AU (1) AU2020397613A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022006259A2 (cg-RX-API-DMAC7.html)
CA (1) CA3155829A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001464A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022007808A2 (cg-RX-API-DMAC7.html)
DK (1) DK4069690T3 (cg-RX-API-DMAC7.html)
ES (1) ES3000984T3 (cg-RX-API-DMAC7.html)
FI (1) FI4069690T3 (cg-RX-API-DMAC7.html)
GB (1) GB201917867D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20250042T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069799T2 (cg-RX-API-DMAC7.html)
IL (1) IL293401B1 (cg-RX-API-DMAC7.html)
LT (1) LT4069690T (cg-RX-API-DMAC7.html)
MX (1) MX2022006654A (cg-RX-API-DMAC7.html)
PL (1) PL4069690T3 (cg-RX-API-DMAC7.html)
PT (1) PT4069690T (cg-RX-API-DMAC7.html)
RS (1) RS66401B1 (cg-RX-API-DMAC7.html)
SA (1) SA522432879B1 (cg-RX-API-DMAC7.html)
SI (1) SI4069690T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400514T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021111142A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016087880A1 (en) 2014-12-05 2016-06-09 Pulmocide Limited Antimycotic compound
CN117510488B (zh) * 2022-07-28 2025-12-05 博瑞制药(苏州)有限公司 一种硫酸艾沙康唑的制备方法
CN117330660A (zh) * 2023-09-14 2024-01-02 广州医科大学附属第一医院(广州呼吸中心) Uplc-ms/ms联用检测艾沙康唑的方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292472C (en) 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
AU2811689A (en) 1987-11-20 1989-06-14 Schering Corporation Tri-and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5039676A (en) 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
DK0736030T3 (da) 1993-12-21 2001-10-29 Schering Corp Fungicide tetrahydrofuraner
US5714490A (en) 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
US5486625A (en) 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
ES2199291T3 (es) 1995-06-02 2004-02-16 Schering Corporation Antifungicos de tetrahidrofurano.
EP0957101A1 (en) 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
PL212985B1 (pl) 2001-04-03 2012-12-31 Schering Corp Ciekla zawiesina zawierajaca przeciwgrzybiczo skuteczna ilosc posakonazolu oraz zastosowanie zmikronizowanych czastek posakonazolu
EP2141159A1 (en) * 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
WO2013036866A1 (en) 2011-09-07 2013-03-14 The Johns Hopkins University Itraconazole analogs and use thereof
WO2016087880A1 (en) * 2014-12-05 2016-06-09 Pulmocide Limited Antimycotic compound

Also Published As

Publication number Publication date
KR20220110726A (ko) 2022-08-09
CN114746415B (zh) 2025-04-11
PT4069690T (pt) 2024-12-13
LT4069690T (lt) 2025-01-10
CN114746415A (zh) 2022-07-12
JP2023505227A (ja) 2023-02-08
EP4509179A2 (en) 2025-02-19
HUE069799T2 (hu) 2025-04-28
CL2022001464A1 (es) 2023-03-24
IL293401B1 (en) 2026-08-01
MX2022006654A (es) 2022-09-07
US20260060980A1 (en) 2026-03-05
CO2022007808A2 (es) 2022-06-30
SMT202400514T1 (it) 2025-01-14
ES3000984T3 (es) 2025-03-04
SA522432879B1 (ar) 2025-01-26
EP4069690A1 (en) 2022-10-12
HRP20250042T1 (hr) 2025-03-14
US12491182B2 (en) 2025-12-09
WO2021111142A1 (en) 2021-06-10
DK4069690T3 (da) 2025-01-20
PL4069690T3 (pl) 2025-03-10
BR112022006259A2 (pt) 2022-06-21
SI4069690T1 (sl) 2025-03-31
IL293401A (en) 2022-07-01
EP4069690B1 (en) 2024-11-13
AU2020397613A1 (en) 2022-06-02
CA3155829A1 (en) 2021-06-10
US20230028714A1 (en) 2023-01-26
GB201917867D0 (en) 2020-01-22
EP4509179A3 (en) 2025-02-26
RS66401B1 (sr) 2025-02-28

Similar Documents

Publication Publication Date Title
JP2017536382A5 (cg-RX-API-DMAC7.html)
HRP20250042T1 (hr) Polimorfi triazolnog antifungalnog spoja pc945
JP2011500779A5 (cg-RX-API-DMAC7.html)
US6407129B1 (en) Azole compounds, their production and their use
Marzi et al. A recent overview of 1, 2, 3‐triazole‐containing hybrids as novel antifungal agents: Focusing on synthesis, mechanism of action, and structure‐activity relationship (SAR)
-H. Zhou et al. Recent researches in triazole compounds as medicinal drugs
JP2023505227A5 (cg-RX-API-DMAC7.html)
EP1254659B1 (en) Stable emulsion compositions
US7078526B2 (en) CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
CN107001343B (zh) 抗真菌的化合物
Schrekker et al. Imidazolium salts as antifungal agents: activity against emerging yeast pathogens, without human leukocyte toxicity
JP5635075B2 (ja) 抗真菌医薬組成物
AR128189A2 (es) Combinaciones fungicidas
JP2017536371A5 (cg-RX-API-DMAC7.html)
NZ613167A (en) Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
REZKI et al. Green ultrasound-assisted three-component click synthesis of novel 1H-1, 2, 3-triazole carrying benzothiazoles and fluorinated-1, 2, 4-triazole conjugates and their antimicrobial evaluation
US20050070551A1 (en) Novel crystalline forms of conazoles and methods of making and using the same
WO2015106283A1 (en) Antifungal compounds
US20090088443A1 (en) Novel crystalline forms of conazoles and methods of making and using the same
JPWO2006118329A1 (ja) 安定な乳化組成物
EP3060549B1 (en) Novel antifungal oxodihydropyridinecarbohydrazide derivative
US20080032994A1 (en) Modified azole compounds as antifungal and antibacterial agents
US20020193384A1 (en) Use of azoles for the preventing skin cancer
EP1742941A1 (en) Novel saperconazole crystalline forms and related processes, pharmaceutical compositions and methods
US6583164B1 (en) Antimycotic drug composition